Oaktree Acquisition Corp. II

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Alvotech is a biotechnology company, which engages in the development and manufacture of biosimilar medicines. The firm is focusing on the development of its product candidates. It operates through the following geographical segments: Europe, North America, Asia, and Other. The company was founded by Róbert Vilhelm Wessman in 2013 and is headquartered in Luxembourg.

Oaktree Acquisition Corp

NEW YORK--(BUSINESS WIRE)--Category: Fund Announcement.

Certain Closed-end Funds Advised by Franklin Templeton Fund Adviser, LLC Announce Appointment of New Chair and Directors

REYKJAVIK, Iceland & LOS ANGELES--(BUSINESS WIRE)--Alvotech Holdings S.A. (“Alvotech S.A.”), a global biotech company focused solely on the development and manufacture of biosimilar medicines for patients worldwide, and Oaktree Acquisition Corp. II (“OACB”) (NYSE: OACB), a special purpose acquisition company sponsored by an affiliate of Oaktree Capital Management, L.P. (“Oaktree”), announced today that their previously announced business combination between Alvotech S.A., OACB and the legal ent

Alvotech and Oaktree Acquisition Corp. II Announce Shareholder Approval of Business Combination

LOS ANGELES--(BUSINESS WIRE)--Oaktree Acquisition Corp. II (NYSE: OACB) (“OACB” or the “Company”) announced today that, assuming satisfaction of the conditions to the closing of its pending business combination with Alvotech Holdings S.A. and Alvotech (“Topco”) (the “Business Combination”), including approval of the Business Combination by the Company's shareholders, Topco, as the surviving entity, intends to list its ordinary shares on The Nasdaq Stock Market LLC and the Nasdaq First North Gro

Oaktree Acquisition Corp. II Announces Delisting of its Securities Effective and Conditional Upon Consummation of its Pending Business Combination with Alvotech

REYKJAVIK, Iceland--(BUSINESS WIRE)--Alvotech Holdings S.A. (“Alvotech”), a global biotech company focused solely on the development and manufacture of biosimilar medicines for patients worldwide, today announced positive results from a confirmatory clinical study for AVT04, Alvotech's proposed biosimilar to Stelara® (ustekinumab). Alvotech is the second company to announce positive results from a patient study utilizing a biosimilar candidate to Stelara®. Teva Pharmaceuticals, a U.S. affiliate

Alvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT04 and Reference Product Stelara®

REYKJAVIK, Iceland--(BUSINESS WIRE)--Alvotech Holdings S.A. (“Alvotech”), a global biotech company focused solely on the development and manufacture of biosimilar medicines for patients worldwide, today announced positive top-line results from a pharmacokinetic (PK) study for AVT04, Alvotech's proposed biosimilar to Stelara® (ustekinumab). The PK similarity study (AVT04-GL-101) utilized a single dose, 3-arm, parallel design to compare pharmacokinetics, safety, tolerability, and immunogenicity o

Alvotech Announces Positive Results from a Pharmacokinetic Similarity Study for AVT04, a Proposed Biosimilar to Stelara®

REYKJAVIK, Iceland & LOS ANGELES--(BUSINESS WIRE)--Alvotech Holdings S.A. (“Alvotech S.A.”), a global biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients worldwide, and Oaktree Acquisition Corp. II (NYSE: OACB), a special purpose acquisition company sponsored by an affiliate of Oaktree Capital Management, L.P. (“OACB”), announced today that the extraordinary general meeting of shareholders of OACB (the “Extraordinary General Meeting”)

Alvotech, Global Biotech Company, and Oaktree Acquisition Corp. II Announce June 7, 2022 Extraordinary General Meeting to Approve Business Combination

REYKJAVIK, Iceland--(BUSINESS WIRE)--Alvotech Holdings S.A. (“Alvotech”), a global biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients worldwide, announced today that, subject to the completion of the announced business combination (the “Business Combination”) between Alvotech, Alvotech Lux Holdings S.A.S. (“the Company”) and Oaktree Acquisition Corp. II (NYSE: OACB.U, OACB, OACB WS) (“OACB”), a special purpose acquisition company wit

Alvotech Improves Access to Capital and Streamlines Path to Expected Public Listing on NASDAQ Stock Exchange

REYKJAVIK, Iceland & BAD VILBEL, Germany--(BUSINESS WIRE)--Alvotech Holdings S.A. (“Alvotech”), a global biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients worldwide, has today announced the resolution of all intellectual property disputes with AbbVie in Europe and selected markets outside of Europe, related to its AVT02 biosimilar candidate. This paves the way for Alvotech's exclusive strategic partner STADA to commercialize AVT02,

Alvotech and STADA Pave Way to Launching HUKYNDRA®(AVT02), a Citrate-free, High-concentration Biosimilar to Humira® by Resolving European Patent Dispute With AbbVie

REYKJAVIK, Iceland--(BUSINESS WIRE)--Alvotech Holdings S.A. (“Alvotech”), a global biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients worldwide, announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company's Biologics Licensing Application (BLA) for ATV02 (100 mg/mL) that includes new data supporting interchangeability between ATV02 and Humira. The data are from a randomized study (AVT02-GL-302

FDA Accepts Alvotech's BLA Supporting Interchangeability for ATV02, a High Concentration, Citrate-Free Biosimilar Candidate for Humira®

REYKJAVIK, Iceland & TOKYO--(BUSINESS WIRE)--Alvotech Holdings S.A. (“Alvotech”), a global biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients worldwide, and Japanese pharmaceutical company Fuji Pharma (“Fuji,” Tokyo Stock Exchange: 4554) announced today that they have agreed to add to their strategic partnership for the development and commercialization of biosimilar medicines in Japan. Under terms of the agreement, Fuji will be gran

Alvotech and Fuji Pharma Expand Partnership for Additional Biosimilar Candidate in Japan

News for Oaktree Acquisition Corp. II Stock (OACB)